crilomus 5 mg hartkapseln
h e x a l aktiengesellschaft (3079284) - tacrolimus 1 h<2>o - hartkapsel - teil 1 - hartkapsel; tacrolimus 1 h<2>o (32463) 5,11 milligramm
crilomus 1 mg hartkapseln
h e x a l aktiengesellschaft (3079284) - tacrolimus 1 h<2>o - hartkapsel - teil 1 - hartkapsel; tacrolimus 1 h<2>o (32463) 1,022 milligramm
tacrolimus - 1 a pharma 5 mg hartkapseln
1 a pharma gmbh (8013083) - tacrolimus 1 h<2>o - hartkapsel - tacrolimus 1 h<2>o (32463) 5,11 milligramm
tacrolimus - 1 a pharma 1 mg hartkapseln
1 a pharma gmbh (8013083) - tacrolimus 1 h<2>o - hartkapsel - tacrolimus 1 h<2>o (32463) 1,022 milligramm
tacrolimus - 1 a pharma 0,5 mg hartkapseln
1 a pharma gmbh (8013083) - tacrolimus 1 h<2>o - hartkapsel - tacrolimus 1 h<2>o (32463) 0,511 milligramm
itraconazol heumann 100 mg hartkapseln
heumann pharma gmbh & co. generica kg (8120809) - itraconazol - hartkapsel - teil 1 - hartkapsel; itraconazol (23401) 100 milligramm
adport 2 mg - hartkapseln
sandoz gmbh - tacrolimus monohydrat -
darunavir sandoz 600 mg – filmtabletten
sandoz gmbh - darunavir -
darunavir sandoz 75 mg – filmtabletten
sandoz gmbh - darunavir -
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.